Optic IconOptic Logo
|
SearchCollectionsBenchmarks
Organization

Jiangnan University Affiliated Hospital

2 abstracts

Abstract
Final overall survival and biomarker analyses of CHOICE-01: A double-blind randomized phase 3 study of toripalimab versus placebo in combination chemotherapy for advanced NSCLC without EGFR/ALK mutations.
Org: State Key Laboratory of Molecular Oncology, National Clinical Research Center for Cancer, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing Chest Hospital, Capital Medical University, Beijing, China, Liaoning Cancer Hospital,
Abstract
A prospective, single-arm, single-center, exploratory clinical study of anlotinib combined with irinotecan in second-line and above treatment of HER-2–negative advanced breast cancer.
Org: Affiliated Hospital of Jiangnan University (Wuxi Fourth People's Hospital), Wuxi No.2 People’s Hospital, Jiangnan University Affiliated Hospital,